Showing 2791-2800 of 3039 results for "".
- Graybug Vision Presents Preclinical Results for Glaucoma Drug Candidate GB-401https://modernod.com/news/graybug-vision-presents-preclinical-results-for-glaucoma-drug-candidate-gb-401/2477332/Graybug Vision presented preclinical study results for GB-401, a novel injectable depot formulation of a proprietary beta-adrenergic antagonist prodrug, as a potential sustained-delivery treatment of up to 6 months for primary open angle glaucoma (POAG), at the American Glaucoma Society annual me
- Companies in US Drug Supply Chain Unveil Pilot Project to Track Counterfeit Medicineshttps://modernod.com/news/companies-in-us-drug-supply-chain-unveil-pilot-project-to-track-counterfeit-medicines/2477315/Several companies, including Pfizer, GlaxoSmithKline, Roche, Eli Lilly, Novartis, Sanofi, Novo Nordisk, Amgen and Gilead Sciences, have created a blockchain-based platform to track prescription products across the supply chain in an effort to better stem the flow of counterfeit medicines, a
- Eyevance Pharmaceuticals Appoints Julie Speed as Chief Commercial Officerhttps://modernod.com/news/eyevance-pharmaceuticals-appoints-julie-speed-as-chief-commercial-officer/2477316/Eyevance Pharmaceuticals has appointed Julie Speed to the position of Chief Commercial Officer. In her new role, Ms. Speed will be responsible for developing the commercial strategy and overseeing the growth of Eyevance’s product portfolio, including Flarex (fluorometholone acetate) 0.1%, Freshk
- Myopia Management Focus of Pipeline Expansion for Leo Lens Pharmahttps://modernod.com/news/myopia-management-focus-of-pipeline-expansion-for-leo-lens-pharma/2477307/Leo Lens Pharma (formerly DBA as Leo Lens Technology Co.) announced it received a notice of allowance from the United States Patent and Trademark Office for a patent for the use of its proprietary MediPrint process to manufacture a contact lens capable of providing enhance
- Schwind Hosts 18th International User Meeting in Hamburghttps://modernod.com/news/schwind-hosts-18th-international-user-meeting-in-hamburg/2477306/A new attendance record was set at the 18th International Schwind User Meeting. Schwind reported that about 260 attendees from more than 50 countries met in Hamburg, Germany, January 23-25, 2020. The Schwind user fami
- Ribomic Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-first-injection-in-the-phase-2-clinical-trial-of-rbm-007-tofu-study-in-subjects-with-wet-amd/2477304/Ribomic announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of wet age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States.</
- Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)https://modernod.com/news/oculis-announces-positive-ocs-01-phase-2-data-in-patients-with-diabetic-macular-edema-dme/2477287/Oculis reported positive data from a phase 2 study of OCS-01, a novel eye drop formulation of dexamethasone, in development for the treatment of diabetic macular edema (DME), according to a company news release. OCS-01 was developed using Oculis’ proprietary Soluble NanoParticle technolog
- Regeneron: Eylea Reduced Risk of Developing Vision-Threatening Events by 75% After 2 Years in Patients With DRhttps://modernod.com/news/regeneron-eylea-reduced-risk-of-developing-vision-threatening-events-by-75-after-two-years-in-patients-with-dr/2477283/Regeneron Pharmaceuticals announced positive 2-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection 2 mg (0.05 mL) in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR). The data were presented for the first time at the Angiogen
- Oxurion Presentation of Positive Topline Data from a Phase 1 Study Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-presentation-of-positive-topline-data-from-a-phase-1-study-evaluating-thr-687-for-the-treatment-of-dme/2477284/Oxurion NV announced that further positive topline data from a phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist for the treatment of diabetic macular edema (DME), was presented by Arshad Khanani, MD, MA, Director of Clinical Research at Sierra Eye Associates, Reno, Nevada,
- Lineage Provides Positive Update on Phase 1/2a Clinical Study of OpRegen for the Treatment of Dry Age-Related Macular Degenerationhttps://modernod.com/news/lineage-provides-positive-update-on-phase-i-iia-clinical-study-of-opregen-for-the-treatment-of-dry-age-related-macular-degeneration/2477278/Lineage Cell Therapeutics a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided an update from its ongoing phase 1/2a clinical study of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry